ClinicalTrials.gg
RecruitingNCT07923214Updated Nov 13, 2026

A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors

A Phase 1 interventional study of CG-7321 and Fulvestrant in Advanced Solid Tumors, Breast Cancer and Ovarian Cancer, sponsored by Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Jul 2024, registered Oct 2026).
  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Nov 13, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,930 studies in Breast Neoplasms with a site in China — 868 open to participants now, 1,065 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
1,030th of 1,520
66 · median 120
Started
2024
with 221 others
Phase 1
171 of 1,930
61 open now
Primary completion
2027-04
later than 642 of 1,064 live
Registered
1,926th of 1,930
by date

Among the 1,930 studies in Breast Neoplasms with a site in China, this one is the 1,030th largest by planned enrollment of the 1,520 interventional ones that give a count, is one of 222 that started in 2024, is one of 171 in phase 1, reaches primary completion later than 642 of the 1,064 other live ones, and was the 1,926th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

868 of the 1,930 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

863 more — sign in →

All 868 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,930 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a Phase I, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CG-7321 capsules as monotherapy or in combination with fulvestrant or letrozole in subjects with advanced solid tumors.

The study consists of:

  • Part Ia (Monotherapy): Dose escalation (accelerated titration followed by 3+3 design) from 2mg to 50mg twice daily (BID), plus dose expansion cohorts in advanced solid tumors including HR+/HER2- breast cancer, ovarian cancer, gastric cancer, and other tumor types.
  • Part Ib (Combination Therapy): Dose escalation of CG-7321 combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer.
Read the detailed description

CG-7321 is a novel oral small molecule CDK2 inhibitor with balanced CDK4/6/9 inhibition potency, being developed for the treatment of advanced solid tumors, being developed for the treatment of advanced solid tumors.

Preclinical studies have demonstrated potent anti-tumor activity in breast cancer, ovarian cancer, and gastric cancer models.

This Phase I study employs a dose escalation design to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of CG-7321.

Part Ia evaluates CG-7321 monotherapy with dose levels of 2mg, 6mg, 12mg, 20mg, 30mg, 40mg, and 50mg BID in a 28-day cycle. Single dosing (Cycle 0) followed by multiple dosing (Cycle 1 onwards) will be evaluated.

Part Ib evaluates CG-7321 in combination with fulvestrant or letrozole in HR+/HER2- advanced breast cancer patients.

Dose expansion cohorts will further evaluate safety, PK, and preliminary efficacy at or near the RP2D in specific tumor types.

Eligible subjects include patients with histologically/cytologically confirmed advanced or metastatic solid tumors who have failed, are intolerant to, or have no effective standard therapy available, or who refuse standard treatment.

Estimated enrollment: 44-66 subjects (Ia: 20-30; Ib: 24-36).

03

Conditions studied

  • Advanced Solid Tumors
  • Breast Cancer
  • Ovarian Cancer
  • Gastric Cancer
  • Other Solid Tumors

Keywords

  • Phase I
  • Dose escalation
  • Advanced solid tumors
  • Pharmacokinetics
  • Maximum tolerated dose
  • CDK2
  • CDK4/6
  • CDK9
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntary signed and compliance with protocol requirements
  • 2. Age ≥18 years, any gender
  • 3. ≥12 weeks
  • 4. (ECOG) performance status 0-1
  • 5. For Part Ia (Monotherapy) dose escalation: patients with cytologically and/or histopathologically confirmed advanced or solid tumors who have failed, are intolerant to, or have no effective standard treatment, or who refuse standard treatment For Part Ib (Combination Therapy) dose escalation: HR+/- advanced breast cancer patients
  • 6. Voluntary provision of tumor tissue specimens (archived within 2 years or fresh tissue)
  • 7. At least one per , version 1.1(RECIST 1.1)
  • 8. Prior anticancer treatment-related toxicities resolved to ≤1 grade (except alopecia)
  • 9. Adequate organ and bone marrow function
  • 10. Negative serum pregnancy test within 7 days before first dose
  • 11. Agreement to use effective from ICF signing to ≥6 months after last dose
  • 12. No breastfeeding during study and ≥6 months after last dose
  • 13. Understanding of study and voluntary written informed consent

Exclusion criteria

Exclusion Criteria:

  • 1. Anticancer therapy (chemotherapy, targeted therapy, biologics, immunotherapy, radiotherapy) within 4 weeks before first dose, or participation in other interventional clinical studies (observational studies excluded)
  • 2. Strong Cytochrome P450 3A4()inhibitors within 2 weeks before first dose
  • 3. Strong Cytochrome P450 2C8(CYP2C8) inhibitors within 2 weeks before first dose
  • 4. Other active within 3 years before first dose (except curable tumors treated radically)
  • 5. Primary Central Nervous System(CNS) tumors or that failed local treatment (stable asymptomatic CNS metastases allowed)
  • 6. Conditions affecting drug absorption or Pharmacokinetics(PK) parameters (e.g., uncontrolled nausea/vomiting, chronic diarrhea, malabsorption syndrome)
  • 7. Uncontrolled or significant cardiovascular disease,
  • 8. Active infection requiring systemic therapy within 2 weeks;
  • 9. Major surgery within 4 weeks before first dose (except minor procedures)
  • 10. Known allergy to study drug or
  • 11. Mental or cognitive impairment affecting study compliance
  • 12. Known alcohol or drug dependence
  • 13. Pregnant or lactating women
  • 14. Investigator deems subject unsuitable for study participation
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    CG-7321 2mg BID

    CG-7321 capsule 2mg, orally twice daily, 28-day cycle. Cycle 0: Single dose on Day 1. Cycle 1 onwards: Continuous dosing.

    Drug: CG-7321

  • Experimental
    CG-7321 6mg BID

    CG-7321 capsule 6mg, orally twice daily, 28-day cycle. Cycle 0: Single dose on Day 1. Cycle 1 onwards: Continuous dosing.

    Drug: CG-7321

  • Experimental
    CG-7321 12mg BID

    CG-7321 capsule 12mg, orally twice daily, 28-day cycle. Cycle 0: Single dose on Day 1. Cycle 1 onwards: Continuous dosing.

    Drug: CG-7321

  • Experimental
    CG-7321 20mg BID

    CG-7321 capsule 20mg, orally twice daily, 28-day cycle. Cycle 0: Single dose on Day 1. Cycle 1 onwards: Continuous dosing.

    Drug: CG-7321

  • Experimental
    CG-7321 30mg BID

    CG-7321 capsule 30mg, orally twice daily, 28-day cycle. Cycle 0: Single dose on Day 1. Cycle 1 onwards: Continuous dosing.

    Drug: CG-7321

  • Experimental
    CG-7321 40mg BID

    CG-7321 capsule 40mg, orally twice daily, 28-day cycle. Cycle 0: Single dose on Day 1. Cycle 1 onwards: Continuous dosing.

    Drug: CG-7321

  • Experimental
    CG-7321 50mg BID

    CG-7321 capsule 50mg, orally twice daily, 28-day cycle. Cycle 0: Single dose on Day 1. Cycle 1 onwards: Continuous dosing.

    Drug: CG-7321

  • Experimental
    CG-7321 30mg BID + Fulvestrant

    CG-7321 30mg orally twice daily + Fulvestrant 500mg IM. HR+/HER2- advanced breast cancer.

    Drug: CG-7321 · Drug: Fulvestrant

  • Experimental
    CG-7321 40mg BID + Fulvestrant

    CG-7321 40mg orally twice daily + Fulvestrant 500mg IM. HR+/HER2- advanced breast cancer.

    Drug: CG-7321 · Drug: Fulvestrant

  • Experimental
    CG-7321 50mg BID + Fulvestrant

    CG-7321 50mg orally twice daily + Fulvestrant 500mg IM. HR+/HER2- advanced breast cancer.

    Drug: CG-7321 · Drug: Fulvestrant

  • Experimental
    CG-7321 30mg BID + Letrozole

    CG-7321 30mg orally twice daily + Letrozole 2.5mg orally once daily. HR+/HER2- advanced breast cancer.

    Drug: CG-7321 · Drug: Letrozole

  • Experimental
    CG-7321 40mg BID + Letrozole

    CG-7321 40mg orally twice daily + Letrozole 2.5mg orally once daily. HR+/HER2- advanced breast cancer.

    Drug: CG-7321 · Drug: Letrozole

  • Experimental
    CG-7321 50mg BID + Letrozole

    CG-7321 50mg orally twice daily + Letrozole 2.5mg orally once daily. HR+/HER2- advanced breast cancer.

    Drug: CG-7321 · Drug: Letrozole

Interventions

  • DrugCG-7321

    Novel oral cyclin-dependent kinase (CDK) inhibitor. Ia dose levels: 2mg, 6mg, 12mg, 20mg, 30mg, 40mg, 50mg BID. Ib dose levels: 30mg, 40mg, 50mg BID. 28-day cycle.

  • Selective estrogen receptor degrader (SERD). 500mg IM on Cycle 1 Day 1 and Day 15, then Day 1 of each subsequent cycle.

  • Aromatase inhibitor. 2.5mg orally once daily, continuous dosing.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicities (DLTs)

    Number of participants experiencing DLTs during DLT evaluation period.

    Time frame: DLT observation period [approximately 28 days]

  2. Maximum Tolerated Dose (MTD)

    The highest dose level at which ≤2/6 evaluable subjects experience DLT.

    Time frame: End of dose escalation phase [approximately 6-12 months]

  3. Recommended Phase 2 Dose (RP2D)

    The dose level recommended for Phase 2 studies.

    Time frame: End of dose escalation phase [approximately 6-12 months]

  4. Adverse Events (AEs) and SAEs

    Incidence and severity of AEs and SAEs, graded per NCI-CTCAE Version 5.0.

    Time frame: From first dose to 30 days after last dose [up to approximately 2 years]

Secondary outcomes

  1. Objective Response Rate (ORR)

    Percentage achieving CR or PR per RECIST v1.1.

    Time frame: Every 8 weeks [up to approximately 2 years]

  2. Disease Control Rate (DCR)

    Percentage achieving CR, PR, or SD per RECIST v1.1.

    Time frame: Every 8 weeks [up to approximately 2 years]

  3. Duration of Response (DoR)

    Time from first documented response to disease progression or death.

    Time frame: From first documented response until disease progression or death [up to approximately 2 years]

  4. Progression-Free Survival (PFS)

    Time from first dose to disease progression per RECIST v1.1 or death.

    Time frame: From first dose until disease progression or death [up to approximately 2 years]

  5. Overall Survival (OS)

    Time from first dose to death from any cause.

    Time frame: From first dose until death [up to approximately 5 years]

  6. Observed plasma maximum concentration (Cmax) of CG-7321 and its metabolite

    Time frame: Cycle 0 Day 1, Cycle 1 Day 1 up to Cycle 6 Day 1 (each cycle is 28 days)

  7. Area under the concentration-time curve (AUC) of CG-7321 and its metabolite

    Time frame: Cycle 0 Day 1, Cycle 1 Day 1 up to Cycle 6 Day 1 (each cycle is 28 days)

  8. Half-life (T1/2) of CG-7321 and its metabolite

    Time frame: Cycle 0 Day 1, Cycle 1 Day 1 up to Cycle 6 Day 1 (each cycle is 28 days)

  9. Time to maximum concentration(Tmax) of CG-7321 and its metabolite

    Time frame: Cycle 0 Day 1, Cycle 1 Day 1 up to Cycle 6 Day 1 (each cycle is 28 days)

Other outcomes

  1. Biomarkers

    Exploratory biomarker analysis including but not limited to CCNE expression levels.

    Time frame: Baseline and during treatment as tissue samples become available [up to approximately 2 years]

  2. Tumor-to-blood drug concentration ratio

    Ratio of CG-7321 and CG1-Mp2 concentrations in tumor tissue versus peripheral blood.

    Time frame: At time of tumor biopsy during treatment [up to approximately 2 years]

07

Study locations

4 of 4 sites recruiting
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
    • Jin Tan · Contacttanjin@cynogen.com · +86-18180770362
    • Fan Wu, MD · Principal investigator
  • Zhongshan Hospital of Dalian University
    Dalian, Liaoning 116000, China
    Recruiting
    • Jin Tan · Contacttanjin@cynogen.com · +86-18180770362
    • Xiang Li, MD · Principal investigator
    • Ruoyu Wang, MD · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Jin Tan · Contacttanjin@cynogen.com · +86-18180770362
    • Jian Zhang, MD · Principal investigator
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
    • Jin Tan · Contacttanjin@cynogen.com · +86-18180770362
    • Ting Luo, MD · Principal investigator
    • Ping Feng, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 33 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 33 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2026 → Apr 2027 and completion Aug 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 6, 2026
StartActual
Jul 2, 2024
Primary completionEst.
Apr 2027was Dec 2026
CompletionEst.
Dec 2027was Aug 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Apr 2027
Nov 13, 2026
Study completion
Aug 2027→Dec 2027
Nov 13, 2026
Enrollment
30→66
Nov 13, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Edited5. For Part Ia monotherapy(Monotherapy) dose escalation: patients with cytologically and/or histopathologically confirmed advanced or metastatic solid tumors who have failed, are intolerant to, or have no effective standard treatment, or who refuse standard treatment For Part Ib (Combination Therapy) dose escalation: HR+/HER2- advanced breast cancer patients
Nov 13, 2026
Interventions
Added Drug: Fulvestrant·Drug: Letrozole. Arms added: CG-7321 30mg BID + Fulvestrant·CG-7321 40mg BID + Fulvestrant·CG-7321 50mg BID + Fulvestrant·CG-7321 30mg BID + Letrozole·CG-7321 40mg BID + Letrozole·and 1 more
All 6

CG-7321 30mg BID + Fulvestrant · CG-7321 40mg BID + Fulvestrant · CG-7321 50mg BID + Fulvestrant · CG-7321 30mg BID + Letrozole · CG-7321 40mg BID + Letrozole · CG-7321 50mg BID + Letrozole

Nov 13, 2026
Title
A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
Nov 13, 2026
Registered
First appeared on the registry
Nov 6, 2026
Show all 2 updates
  1. Nov 13, 2026
    Primary completion Dec 2026→Apr 2027
    Study completion Aug 2027→Dec 2027
    Enrollment 30→66
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Edited5. For Part Ia monotherapy(Monotherapy) dose escalation: patients with cytologically and/or histopathologically confirmed advanced or metastatic solid tumors who have failed, are intolerant to, or have no effective standard treatment, or who refuse standard treatment For Part Ib (Combination Therapy) dose escalation: HR+/HER2- advanced breast cancer patients
    Interventions Added Drug: Fulvestrant·Drug: Letrozole. Arms added: CG-7321 30mg BID + Fulvestrant·CG-7321 40mg BID + Fulvestrant·CG-7321 50mg BID + Fulvestrant·CG-7321 30mg BID + Letrozole·CG-7321 40mg BID + Letrozole·and 1 more
    All 6

    CG-7321 30mg BID + Fulvestrant · CG-7321 40mg BID + Fulvestrant · CG-7321 50mg BID + Fulvestrant · CG-7321 30mg BID + Letrozole · CG-7321 40mg BID + Letrozole · CG-7321 50mg BID + Letrozole

    Title A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    + 5 other changes: index terms, verification date, description, conditions and design details
  2. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07923214
Lead sponsor
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Jul 2, 2024
Primary completion
Apr 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Ke Lan
Contact
lanke@cynogen.com
+86-13982078904

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion